Malignant Mesothelioma

+ -Text Size

Other Resources and References TOPICS

References: Malignant mesothelioma detailed guide

Alexander HR Jr, Bartlett DL, Pingpank JF, et al. Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery. 2013;153:779-786.

American Joint Committee on Cancer. Pleural mesothelioma. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 271-274.

Arrieta Ó, Medina LA, Estrada-Lobato E, et al. First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer. 2012;106:1027-1032.

Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14:1104-1111.

Haithcock BE, Zagar TM, Zhang L, Stinchcombe TE. Chapter 73: Diseases of the pleura and mediastinum. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181:1383-1390.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma--an update on treatment. Cancer Treat Rev. 2012;38:605-612.

National Cancer Institute. Physician Data Query (PDQ). Malignant Mesothelioma: Treatment. 2014. Accessed at www.cancer.gov/cancertopics/pdq/treatment/malignantmesothelioma/HealthProfessional on March 4, 2015.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. V.1.2015. Accessed at www.nccn.org/professionals/physician_gls/pdf/mpm.pdf on March 4, 2015.

Nowak AK, Millward MJ, Creaney J, et ak. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012;7:1449-1456.

Pan X, Day W, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Resp Crit Care. 2005;172:1019-1025.

Pass HI, Carbone M, Krung LM, Rosenzweig KE. Chapter 114: Benign and malignant mesothelioma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015.

Price B, Ware A. Mesothelioma trends in the United States: An update based on Surveillance Epidemiology and End Results program date for 1973-2003. Am J Epidemiol. 2004;159:107-112.

Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.

Rusch VW, Giroux D, Kennedy C, et al; IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631-1639.

Sterman DH, Haas A, Moon E, et al. A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011;184:1395-1399.

Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-1025.

Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081-2090.


Last Medical Review: 05/18/2015
Last Revised: 05/18/2015